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AN IMPROVED OPTIMISTIC THREE-STAGE MODEL FOR THE
SPREAD OF HIV AMONGST INJECTING INTRAVENOUS
DRUG USERS
David Greenhalgh and Wafa Al-Fwzan
Department of Mathematics and Statistics, University of Strathclyde,
Livingstone Tower, 26, Richmond Street, Glasgow G1 1XH, U.K.
Abstract. We start off this paper with a brief introduction to modeling Hu-
man Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syn-
drome (AIDS) amongst sharing, injecting drug users (IDUs). Then we describe
the mathematical model which we shall use which extends an existing model
of the spread of HIV and AIDS amongst IDUs by incorporating loss of HIV
infectivity over time. This is followed by the derivation of a key epidemiological
parameter, the basic reproduction number R0. Next we give some analytical
equilibrium, local and global stability results. We show that if R0 ≤ 1 then
the disease will always die out. For R0 > 1 there is the disease-free equilib-
rium (DFE) and a unique endemic equilibrium. The DFE is unstable. An
approximation argument shows that we expect the endemic equilibrium to be
locally stable. We next discuss a more realistic version of the model, relaxing
the assumption that the number of addicts remains constant and obtain some
results for this model. The subsequent section gives simulations for both mod-
els confirming that if R0 ≤ 1 then the disease will die out and if R0 > 1 then if
it is initially present the disease will tend to the unique endemic equilibrium.
The simulation results are compared with the original model with no loss of
HIV infectivity. Next the implications of these results for control strategies are
considered. A brief summary concludes the paper.
1. Introduction. HIV/AIDS is a viral disease discovered in the 1980’s. Untreated
infection with HIV eventually leads to AIDS. The main potential transmission routes
are: (i) homosexual or heterosexual contact with an infected person; (ii) sharing
needles or syringes with an infected person; (iii) blood transfusion and (iv) trans-
mission from mother to child. In the past blood transfusion has been an important
transmission route but it is now very rare in countries where blood is screened for
HIV antibodies. Transmission from mother to child is still a significant issue even
though there are modern day drugs available which can greatly reduce the risk.
In the past when knowledge of how HIV was transmitted was just developing
transmission amongst IDUs was a major problem. In many parts of the world HIV
prevalence reached 40% and above just one to two years after HIV entered the IDU
population [18]. [15] estimated that the proportion of HIV infections caused by
injecting drug use is:
• 50 to 90% in Eastern Europe, Central and Eastern Asia and the Pacific;
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• 25 to 50% in North America and Western Europe;
• 10 to 25% in Latin America;
• 1 to 10% in Southern and South-Eastern Asia; and
• less than 1% in sub-Saharan Africa (cited in [19]).
Our model is based on an original paper by Kaplan [7] who considers the spread of
HIV/AIDS via drug use in “shooting galleries” where addicts meet to inject drugs
and share needles. The spread of the disease was modeled using two differential
equations:
dπ
dt
= (1 − π)λβα − µπ
and
dβ
dt
= λγπ − λγβ(1 − (1− π)(1 − θ)).
β(t) is the fraction of syringes infected and π(t) is the fraction of addicts infected
at time t. There are m syringes and n addicts in the population. λ is the per
addict injection rate, µ is the rate at which addicts leave the sharing, injecting
population and γ = n/m is the gallery ratio of addicts to needles. α is the infection
probability per injection, and θ is the flushing probability, the probability that an
initially susceptible addict leaves an infected syringe uninfected after a single use.
A key epidemiological parameter is R0, the basic reproduction number. For R0 ≤ 1
we expect the disease to die out, but for R0 > 1 we expect the disease to take off
[5].
Kaplan and O’Keefe [10] performed a management science based study of a
model loosely based on Kaplan’s original model. They developed a syringe tracking
and testing system that provided data on HIV transmission. They examined the
impact of cleaning and bleaching of infectious needles prior to use and allowing used
syringes to be removed and replaced by unused syringes in the needle population.
Kaplan and O’Keefe’s model suggested that the long-term prevalence of HIV in
addicts could be reduced by up to 33% by implementation of a needle exchange. As
a result Connecticut legislation was changed to allow needle exchanges to operate
on a “one for one” basis. Also legislation was changed in California, New York and
Massachusetts to allow needle exchanges to be implemented and developed.
These models assume that all addicts and needles are equally infectious through-
out the entire infectious period. In reality addicts pass through three stages of HIV
infectivity: an initial highly infectious stage, a second stage of low infectivity and
a third stage of medium infectivity before developing clinical symptoms of AIDS.
Greenhalgh and Lewis looked at incorporating this into the models. In [6] they split
both addicts and needles into three infectious stages. A needle used by an infected
or susceptible addict is left in the infectious state of the last person to use it (“The
Optimistic Model”). We shall extend this model in the paper. Lewis and Green-
halgh [13] also split addicts and needles into three infectious classes. This time a
needle used by an infected or susceptible addict is left in the higher infectious state
of its initial infectious state or the state of the last person to use it (“The Pessimistic
Model”).
2. The Model. Consider the “Optimistic Model” of Greenhalgh and Lewis [6]. In
reality HIV-infected needles do not remain infected indefinitely but lose infectivity
over time. Our target is to examine how addicts and needles interact with each other
AN IMPROVED OPTIMISTIC THREE-STAGE MODEL 3
under extended hypotheses that an infectious needle in the i’th stage of infectivity
becomes virus-free with rate σi, i = 1,2,3.
The model assumes:
(1) All sharing of drug equipment occurs in shooting galleries. There are m shoot-
ing galleries (equivalently m “kits” of drug injection equipment are in circulation)
and addicts select shooting galleries or “kits” at random. All addicts inject once
per visit to a shooting gallery. There are n addicts and the gallery ratio γ = n/m.
(2) Each addict visits shooting galleries in accordance with a Poisson process of
rate λ, independently of the actions of other addicts.
(3) Injection equipment becomes infected if it is used by an infected addict.
Injection equipment always takes on the infectivity characteristics of the last user.
Any uninfected addict who uses injection equipment is exposed to HIV.
(4) The random variability in the fraction of infected addicts and needles at time
t is sufficiently small to be ignored.
(5) Infectious addicts depart the population for reasons other than developing
full-blown AIDS (such as deaths from other causes, treatment or relocation) at per
capita rate µ and are immediately replaced by other addicts.
(6) An addict effectively cleans (bleaches) the injection equipment prior to use
with probability φ.
(7) Each needle is exchanged for an uninfected needle according to a Poisson
process with rate τ . This corresponds to needle exchange.
(8) Given exposure to an infectious needle in state i infectivity a susceptible addict
becomes infected with probability αi for i = 1,2,3. αi is the infectiousness of a state
i needle. The only way addicts can become infected is through sharing needles.
(9) After initial infection an addict is defined to be acutely infectious and enters
the asymptomatic stage according to a Poisson process with rate δ1.
(10) Asymptomatic addicts enter the pre-AIDS stage according to a Poisson process
with per capita rate δ2.
(11) Pre-AIDS addicts enter the full-blown AIDS stage according to a Poisson
process with per capita rate δ3. At this stage addicts leave the sharing, injecting
population. These addicts are immediately replaced by susceptible addicts.
The spread of the disease is given by
dπ1
dt
=
(
1−
3∑
i=1
πi
)
λ(α1β1 + α2β2 + α3β3)(1 − φ)− (µ+ δ1)π1, (1)
dπ2
dt
= δ1π1 − (µ+ δ2)π2,
dπ3
dt
= δ2π2 − (µ+ δ3)π3,
and
dβj
dt
= λγ(πj − βj)− βj(τ + σj), for j = 1, 2, 3,
with suitable initial conditions. Here for i, j = 1,2,3, πi is the fraction of all addicts
who are stage i infected addicts and βj is the fraction of all needles which are
infected needles in state j.
3. Basic Reproduction Number R0. R0 is defined as the expected number of
secondary addicts infected by a single newly infected addict entering the DFE (i.e.
addicts infected directly via sharing a syringe with the original infected addict).
A newly infected addict infects λ/(µ+ δ1) syringes in stage 1, and progresses to
stage 2 with probability δ1/(µ + δ1). A stage 2 infected addict infects λ/(µ + δ2)
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syringes in stage 2 and progresses to stage 3 with probability δ2/(µ+ δ2). A stage 3
infected addict infects λ/(µ+δ3) syringes in stage 3. For i = 1,2,3, a state i infected
needle is used by susceptible addicts at rate λγ (we can assume that all addicts are
susceptible as we are near the DFE) and infects
λγαi(1− φ)
λγ + τ + σi
=
αi(1− φ)
1 + τˆ + σˆi
of them, where τˆ = τ/λγ and σˆ = σi/λγ. Hence R0 is given by
λ
µ+ δ1
(1− φ)
[
α1
1 + τˆ + σˆ1
+
α2δ1
(1 + τˆ + σˆ2)(µ+ δ2)
+
α3δ1δ2
(1 + τˆ + σˆ3)(µ+ δ2)(µ+ δ3)
]
.
(2)
We expect that the disease takes off if R0 > 1 and dies out if R0 ≤ 1. We shall
explore this in the next two sections.
4. Equilibrium and Stability Results. The equilibrium and stability results
follow along the lines of [6]. Full details are given in [1].
Theorem 4.1. (i) For R0 ≤ 1 the only equilibrium is the DFE πi = βj = 0 for
i, j = 1,2,3. This is globally asymptotically stable (GAS).
(ii) For R0 > 1 the DFE still exists and is unstable. There is also a unique endemic
equilibrium πi = π
∗
i and βj = β
∗
j for i, j = 1,2,3.
Proof. For i, j = 1,2,3, let π∗i denote the equilibrium proportion of addicts who
are infected and in infective stage i and β∗j denote the equilibrium proportion of
needles which are infected and in infective state j. We write π∗ = π∗1+π
∗
2+π
∗
3 , β
∗ =
β∗1 + β
∗
2 + β
∗
3 and L = 1+
δ1
µ+δ2
+ δ1δ2(µ+δ2)(µ+δ3) . We can use the equilibrium versions
of (1), (1)(ii)-(vi) first to express π∗i and β
∗
j in terms of π
∗ and then (1)(i) to give
an equation for π∗. We deduce that there are two equilibria:
(i) (π∗, β∗) = (0, 0) which is always possible;
(ii) π∗ = 1−
1
R0
, β∗ =
(R0 − 1)F
LR0
,
where F =
1
1 + τˆ + σˆ1
+
δ1
(1 + τˆ + σˆ2)(µ+ δ2)
+
δ1δ2
(1 + τˆ + σˆ3)(µ+ δ2)(µ+ δ3)
,
which is possible if and only if R0 > 1.
Write f∞ = lim supt→∞ f(t). For R0 ≤ 1 global stability of the DFE follows
from the results:
π∞2 ≤
δ1π
∞
1
µ+ δ2
, π∞3 ≤
δ1δ2π
∞
1
(µ+ δ2)(µ+ δ3)
, β∞1 ≤
π∞1
1 + τˆ + σˆ1
,
β∞2 ≤
δ1π
∞
1
(µ+ δ2)(1 + τˆ + σˆ2)
and β∞3 ≤
δ1δ2π
∞
1
(µ+ δ2)(µ+ δ3)(1 + τˆ + σˆ3)
,
along the lines of [6].
To show instability of the DFE whenR0 > 1 we obtain the characteristic equation
of the linearization about this equilibrium in the form
ω6 + a1ω
5 + a2ω
4 + a3ω
3 + a4ω
2 + a5ω + a6 = 0,
where
a6 = (µ+ δ1)(µ+ δ2)(µ+ δ3)(λγ + τ + σ1)(λγ + τ + σ2)(λγ + τ + σ3)(1 −R0),
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when the result is obvious by the Routh-Hurwitz conditions [14].
Let π = π1 + π2+ π3, the total fraction of infected addicts and β = β1 + β2+ β3,
the total fraction of infected needles at time t.
Theorem 4.2. If R0 > 1 and either π(0) > 0 or β(0) > 0 then there exists ǫ > 0
and η > 0 such that
πi ≥ ǫπ
∗
i , βi ≥ ǫβ
∗
i , i = 1,2,3 ∀t ≥ η.
Here ǫ is a fixed positive and small value independent of the initial conditions.
Proof. Define f∞ = lim inft→∞ f(t). The proof proceeds along the lines of the
corresponding result in [6]. From the differential equations (1) we show that
π2,∞ ≥
δ1π1,∞
µ+ δ2
, π3,∞ ≥
δ1δ2π1,∞
(µ+ δ2)(µ+ δ3)
, β1,∞ ≥
π1,∞
1 + τˆ + σˆ1
,
β2,∞ ≥
δ1π1,∞
(µ+ δ2)(1 + τˆ + σˆ2)
and β3,∞ ≥
δ1δ2π1,∞
(µ+ δ2)(µ+ δ3)(1 + τˆ + σˆ3)
.
Then the result of Theorem 4.2 will follow from showing that π1,∞ is bounded
strictly away from zero with lower bound dependent only on the model parameters
not the initial conditions.
We need the following lemma proved analogously to the corresponding result in
[6].
Lemma 4.3. If at least one of π1(t), π2(t), π3(t), β1(t), β2(t) and β3(t) > 0 at
t = 0 then there exists ∆t > 0 such that
π1(∆t), π2(∆t), π3(∆t), β1(∆t), β2(∆t) and β3(∆t) > 0.
If π1,∞ ≥
1
2ǫπ
∗
1 then Theorem 4.2 follows from the lower bounds obtained previously.
Suppose from now on that π1,∞ <
1
2ǫπ
∗
1 . Define t0 = inf{η ≥ ∆t : π1(η) <
1
2ǫπ
∗
1}
and t1 = inf{η ≥ t0 : π1(η) >
1
2ǫπ
∗
1}. We next show that all components will
become small if π1 becomes small.
Lemma 4.4. There is a value T 1 > 0 such that for t0 + T 1 < t1, then 0 < π2 <
(12+∆)π
∗
2ǫ for every t ∈ [t0+T 1, t1]. Here T 1 depends only on the model parameters
and the small parameters ∆ > 0 and ǫ, not on the initial conditions.
Proof. Straightforward from (1)(ii) and the fact that π1 ≤
1
2ǫπ
∗
1 in [t0, t1].
A similar argument shows that there is a value T 2 > 0 such that for t0+T 1+T 2 <
t1 then 0 < π3 < (
1
2 + 2∆)π
∗
3ǫ for all t ∈ [t0 + T 1 + T 2, t1], where T 2 depends only
on the model parameters, ∆ and ǫ. Also there exist T 3, T 4 and T 5 > 0 dependent
only on the model parameters, ∆ and ǫ, such that 0 < β1 < (
1
2 + ∆)ǫβ
∗
1 , for
t ∈ [t0 + T 3, t1], 0 < β2 < (
1
2 + 2∆)ǫβ
∗
2 , for t ∈ [t0 + T 1 + T 4, t1], and 0 < β3 <
(12 + 3∆)ǫβ
∗
3 , for t ∈ [t0 + T 1 + T 2 + T 5, t1].
We have the following lemma:
Lemma 4.5. Let t†1 = t0 +max[T 3, T 1 + T 4, T 1 + T 2 + T 5, T 1 + T 2 + T 6] where
T 6 is defined in the proof of the lemma. If π1(t) goes under
1
2 ǫπ
∗
1 at time t0 then it
rises up to 12ǫπ
∗
1 by at least time t
†
1, where t
†
1 − t0 is finite and dependent only on
the model parameters, ∆ and ǫ, not on the initial conditions.
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Proof. Consider the matrix
J2(ǫ) =


−(µ+ δ1) 0 0 λα1(1− φ)(1 − ǫ2)
δ1 −(µ+ δ2) 0 0
0 δ2 −(µ+ δ3) 0
λγ 0 0 −(λγ + τ + σ1)
0 λγ 0 0
0 0 λγ 0
λα2(1− φ)(1 − ǫ2) λα3(1− φ)(1 − ǫ2)
0 0
0 0
0 0
−(λγ + τ + σ2) 0
0 −(λγ + τ + σ3)


.
When ǫ2 = 0 we have the linearized stability matrix at the DFE. If ω1(ǫ2) is the
dominant eigenvalue of J2(ǫ) then ω1(ǫ2) → ω1(0) as ǫ2 → 0 (see [6]). The proof
follows along the lines of the corresponding result in [6].
Choose 1 > ǫ2 > 0 such that ω1(ǫ2) is positive. Then choose ǫ to be small enough
so that 12ǫπ
∗
1 + (
1
2 +∆)ǫπ
∗
2 + (
1
2 + 2∆)ǫπ
∗
3 < ǫ2. The required result of Lemma 4.5
is achieved when t0 + T 1 + T 2 > t1, otherwise for t1 ≥ t ≥ t0 + t2 we have
dx
dt
≥ J(ǫ2)x
where x = (π1, π2, π3, β1, β2, β3). Let e = (e1, e2, e3, e4, e5, e6) be the positive left
eigenvector of J(ǫ2) corresponding to the Perron eigenvalue ω1(ǫ2) [15]. An ar-
gument similar to [6] implies that after time t0 + t2 + T 6, e.x(t) strictly exceeds
e.(12ǫπ
∗
1 , (
1
2 +∆)ǫπ
∗
2 , (
1
2 +2∆)ǫπ
∗
3 , (
1
2 +∆)ǫβ
∗
1 , (
1
2 +2∆)ǫβ
∗
2 , (
1
2 +3∆)ǫβ
∗
3), where T 6
is dependent only on the model parameters, ǫ and ∆. This is a contradiction unless
t1 ≤ t0 +max[T 1, T 1 + T 2, T 3, T 1 + T 4, T 1 + T 2 + T 5, t2 + T 6] proving Lemma
4.5.
A similar argument implies that π1 must eventually rise above
1
2ǫπ
∗
1 and each
subsequent time that π1 drops under
1
2ǫπ
∗
1 it must tend back to that value by at most
time T later where T depends only on the model parameters, ∆, ǫ and ǫ2. (1)(i) now
implies that π1 ≥
1
2ǫπ
∗
1 exp[−(µ + δ1)T ], hence π1,∞ ≥
1
2ǫπ
∗
1 exp[−(µ + δ1)T ] > 0
and the result of Theorem 4.2 follows from previous comments.
For R0 > 1 local stability of the endemic equilibrium is too complicated to show
directly. However as the timescale on which the βi change (days) is much faster than
that on which the πi change (years) it is possible to approximate the relationship
between the βi(t) and the πi(t) as
βi(t) =
πi(t)
1 + τˆ + σˆi
for i = 1, 2, 3.
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With this approximation we have
dπ1
dt
= (1− π)λ(1 − φ)
(
π1α1
1 + τˆ + σˆ1
+
π2α2
1 + τˆ + σˆ2
+
π3α3
1 + τˆ + σˆ3
)
− (µ+ δ1)π1,
dπ2
dt
= δ1π1 − (µ+ δ2)π2 and
dπ3
dt
= δ2π2 − (µ+ δ3)π3.
Theorem 4.6. The approximate model has the same R0 and equilibria as the full
model. Moreover in the approximate model the unique endemic equilibrium is always
locally asymptotically stable (LAS) when it exists.
Proof. It is straightforward to show that the approximate model has the same R0
and equilibria as the full model. For R0 > 1 we linearize the approximate model
about the unique endemic equilibrium (π∗1 , π
∗
2 , π
∗
3). We find that the characteristic
equation is
ω3 + a1ω
2 + a2ω + a3 = 0,
where a1 = (µ+ δ2 + µ+ δ3) +
µ+ δ1
L
(R0 − 1)
+
µ+ δ1
E
(
α2δ1
(1 + τˆ + σˆ2)(µ+ δ2)
+
α3δ1δ2
(1 + τˆ + σˆ3)(µ+ δ2)(µ + δ3)
)
,
a2 = (µ+ δ2)(µ+ δ3) +
µ+ δ1
L
(R0 − 1)(δ1 + µ+ δ2 + µ+ δ3)
+
µ+ δ1
E
(
α2δ1(µ+ δ3)
(1 + τˆ + σˆ2)(µ+ δ2)
+
α3δ1δ2
(1 + τˆ + σˆ3)(µ+ δ2)
+
α3δ1δ2
(1 + τˆ + σˆ3)(µ+ δ3)
)
,
and a3 =
µ+ δ1
L
(δ1δ2 + δ1(µ+ δ3) + (µ+ δ2)(µ+ δ3))(R0 − 1).
Here E =
α1
1 + τˆ + σˆ1
+
α2δ1
(1 + τˆ + σˆ2)(µ+ δ2)
+
α3δ1δ2
(1 + τˆ + σˆ3)(µ+ δ2)(µ+ δ3)
.
It follows that a1 > 0, a3 > 0 and a1a2 > a3, therefore the Routh-Hurwitz condi-
tions are satisfied and the unique endemic equilibrium is LAS when it exists.
4.1. Global Stability of the Endemic Equilibrium. We now return to the full
model. We suspect that if R0 > 1 and disease is initially present then the system
will approach the unique endemic equilibrium. We have not been able to show this
analytically, although in the next section we shall see that simulation suggests it.
However we can show the following result:
We define M† to be the matrix:
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

µ+ λǫ(1 − φ) −δ1 0 −λγ 0 0
0 µ+ δ1 + δ2 −δ2 −λγ −λγ 0
−δ3 −δ1 µ+ δ3 −λγ 0 −λγ
−(1− π∗)λα1(1 − φ) 0 0 M
+
44 0 0
−(1− π∗)λα2(1 − φ) 0 0 0 M
+
55 0
−(1− π∗)λα3(1 − φ) 0 0 0 0 M
+
66


,
where M+44 = λγ + τ + σ1, M
+
55 = λγ + τ + σ2 and M
+
66 = λγ + τ + σ3.
Theorem 4.7. If R0 > 1, (µ+ δ2+ δ1)(µ+ δ3) > δ1δ2, det(M
†) > 0 and disease is
initially present then at large times the disease approaches the endemic equilibrium.
Proof. Along the lines of the corresponding result in [6]. Full details are given in
[1].
5. Model with a Variable Population Size. One of the drawbacks of the model
just discussed is that it assumes that the addict population size is constant for math-
ematical simplicity and it would be more realistic to model new addicts entering
the population and dying from AIDS by using a variable population size. This is
discussed by [12] for a simpler model. We follow [4] and assume that new addicts
come into the sharing injecting population at rate cnν , where 0 ≤ ν ≤ 1 and c is
positive. If ν = 1 then there is feedback from the current users who recruit new
naive users into the sharing injecting population. If ν = 0 then we have constant
recruitment of new addicts as discussed for HIV/AIDS amongst gay men by [2] and
[3].
Addicts in stage 3 may develop full-blown AIDS (at per capita rate δ3) when
they are assumed to cease sharing syringes. All addicts may stop sharing syringes
for other reasons (i.e. giving up drugs, going to prison, entering treatment) at per
capita rate µ. We also assume that the gallery ratio is constant so that the total
number of addicts at time t, n(t), is equal to γm(t) where m(t) is the total number
of syringes at time t. With these modified assumptions the differential equations
which describe the progress of the disease are:
dπ1
dt
=
(
1−
3∑
i=1
πi
)
λ(α1β1 + α2β2 + α3β3)(1− φ) − (µ+ δ1)π1 −
π1
n
dn
dt
, (3)
dπ2
dt
= δ1π1 − (µ+ δ2)π2 −
π2
n
dn
dt
,
dπ3
dt
= δ2π2 − (µ+ δ3)π3 −
π3
n
dn
dt
,
dβj
dt
= λγ(πj − βj)− βj(τ + σj)−
βj
n
dn
dt
, for j = 1, 2, 3,
and
dn
dt
= cnν − µn− δ3π3n.
The initial conditions are πi(0), βj(0), n(0) ≥ 0 for i, j = 1,2,3, π1(0) + π2(0) +
π3(0) ≤ 1 and β1(0) + β2(0) + β3(0) ≤ 1. We take 0 < ν < 1.
For this model there is a unique DFE given by
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(π1, π2, π3, β1, β2, β3, n) = (0, 0, 0, 0, 0, 0, n
∗
0)
where n∗0 = (
µ
c
)
1
ν−1 . R0 is the same as in the constant population size model. We
have the following results:
Theorem 5.1. For the model given by (3):
(i) If R0 ≤ 1 then the only possible equilibrium is the DFE which is GAS.
(ii) If R0 > 1 then the DFE exists and is unstable, but there is also a unique
endemic equilibrium given by
(π1, π2, π3, β1, β2, β3, n) = (π
∗
1 , π
∗
2 , π
∗
3 , β
∗
1 , β
∗
2 , β
∗
3 , n
∗
e)
where π∗1 , π
∗
2 , π
∗
3 , β
∗
1 , β
∗
2 and β
∗
3 are the equilibrium values discussed in Section 4 and
n∗e = (
µ+δ3pi
∗
3
c
)
1
ν−1 .
Proof. The equilibrium results are straightforward. For R0 ≤ 1 we can express
equations (3) in terms of the absolute numbers of infected addicts and infected
needles and show that the DFE is GAS using the same methods as in Theorem 4.1,
i.e. the proof of the corresponding result in [6].
For R0 > 1 we proceed as in [12]. The roots of the characteristic equation are
ω1 = νcn
∗
0
ν−1−µ = µ(ν−1) < 0 and the roots of the characteristic equation of the
linearization of system (1) about the DFE of that model. Theorem 5.1 follows.
6. Simulations. We performed simulations to illustrate our analytical results. The
parameter values were estimated from the literature and real data. The simulations
suggest that for R0 > 1 if the disease is initially present then it will tend to the
unique endemic equilibrium. They also confirm that if R0 ≤ 1 then the disease will
eventually die out.
We use the value 100 : 1 : 10 for α1 : α2 : α3 suggested by [13]. Other papers
use different values for this ratio (i.e. [17]) but the ratios 100 : 1 : 10 are better
supported by the data. We also have that σ−1, the average time until a needle
becomes virus-free, is a weighted average of the mean time until an infectious needle
becomes virus-free over the three types of infectious needles
σ−1 =
β∗1
β∗
σ−11 +
β∗2
β∗
σ−12 +
β∗3
β∗
σ−13 . (4)
If we also make the reasonable assumption that the average time until an infectious
needle becomes virus-free is proportional to its viral load we have that
σ−1i = Kαi (5)
for i = 1,2,3, for some constant K.
To estimate σ1, σ2 and σ3 we use a simple approximation argument. From [7] we
know that an average infected needle becomes virus-free in about a week, so σ−1
= 52 per year. From [10] we have that β∗ = 0.675. From [13] we have that α2 =
0.0011, α1 = 0.11, α3 = 0.011, β
∗
1 = 0.024, β
∗
2 = 0.562 and β
∗
3 = 0.088. It is then
straightforward from (4) that σ1 = 2.9569 per year, σ2 = 295.69 per year and σ3 =
29.569 per year. Note that this is only an approximate method as the estimate of
α2 in [13] assumes that σ1 = σ2 = σ3 = 0 per year and it would ideally have been
better to estimate α2 and K simultaneously from (4) and (5) although this would
have been extremely complicated.
Having an initial approximate estimate of σ1, σ2 and σ3 if we were then to perform
simulations with the same values of α1, α2 and α3 as in [13] looking at equation (2)
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we see that we would automatically decrease R0. So instead we increase α2 to
compensate for this so that with our new parameter estimates of σ1, σ2 and σ3 we
have R0 = 2.92 as in [13], using the parameter values in that paper. When we
do this we find that α2 = 0.00133 so α1 = 0.133 and α3 = 0.0133, only a small
difference from the original values.
[9] estimate n∗0 = 2, 300 for New Haven, USA, but this will vary from location to
location. ν is difficult to estimate as we have no data. We take n(0) = n∗0 = 5,000
and ν = 0.05 to give reasonably large sizes in all subpopulations. This implies that
c = µn∗0
1−ν = 435.36 per year.
We start with the constant population size model (1). For our first simulation
the remaining parameter values based on realistic estimates from the literature are
λ = 246.22 per year [10], γ = 0.908 [11], µ = 0.1333 per year [4], φ = 0.64 [6], τ =
15.53 per year [8], δ1 = 8.0 per year, δ2 = 0.1154 per year and δ3 = 0.8276 per year
[13]. These parameters give R0 = 2.001. Figure 1 shows a typical simulation over
15 years. The starting values are π1(0) = 0.0791, π2(0) = 0.249, π3(0) = 0.022,
β1(0) = 0.092, β2(0) = 0.100 and β3(0) = 0.020. We see that both the fractions of
infected addicts and needles tend to their unique endemic equilibrium values as time
becomes large. The simulation was repeated with several sets of parameter values
giving R0 > 1 and several different starting values. In each case provided that
the disease was initially present in either addicts or needles the disease eventually
approaches the unique endemic equilibrium.
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Figure 1. Typical simulation when R0 > 1.
To verify that the disease does indeed die out if R0 < 1 several other simulations
were performed with different starting values and parameter sets with R0 < 1 and
in each case the disease died out. This confirms the results of Theorem 4.1.
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We may ask whether the introduction of loss of HIV infectivity over time makes
any practical difference to the results of our model. The answer seems to be that
it makes a small but practically significant difference to the results. For the model
parameters above we find that π∗1 = 0.01350, π
∗
2 = 0.4340, π
∗
3 = 0.05215, β
∗
1 =
0.01247, β∗2 = 0.1815, β
∗
3 = 0.04340 and R0 = 2.001. With the same parameter
values except that σ1 = σ2 = σ3 = 0 per year, α2 = 0.0011, α1 = 0.11 and α3 =
0.011, see above discussion, we find that π∗1 = 0.01290, π
∗
2 = 0.4150, π
∗
3 = 0.04983,
β∗1 = 0.01206, β
∗
2 = 0.3880, β
∗
3 = 0.04660 and R0 = 1.9146. Hence we see that there
is a small but significant difference in the equilibrium number of infected addicts
and R0 (R0 differs by about 5%) but there is a big difference between the numbers
of stage 2 infected syringes. Figure 2 shows the simulation of the model with those
parameter values and the same starting values as in Figure 1.
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Figure 2. Corresponding simulation with σ1 = σ2 = σ3 = 0 and
R0 > 1.
We now move on to simulation for the variable population size model. Figure
3 shows a simulation with parameter values as discussed above, starting values for
β1, β2, β3, π1, π2 and π3 as in the other two simulations, and n(0) = n
∗
0 = 5,000.
In this figure for j = 1,2,3, Ij and ij denote respectively the number of addicts
and needles in infectious state j. Note that the simulation tends to the unique
endemic equilibrium values but that the time taken for it to do this is larger than
in the constant population size model. This is similar to the corresponding result
discussed in [12]. We performed simulations with various parameter values and
initial conditions for the variable population size model and the results were as
expected. Provided that R0 ≤ 1 the system ultimately tended to the unique DFE
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but if R0 > 1 and HIV was initially present, either in addicts or needles, the system
tended to the unique endemic equilibrium as time became large.
0 10 20 30 40
Time in Years
0
1000
2000
3000
4000
5000
N
um
be
r
I
I
I
i
i
i
n
1
1
2
3
2
3
Figure 3. Simulation for variable population size model.
7. Implications for Control Strategies. Part of the power of Kaplan’s original
model was that it gave us the ability to explore how interventions or control levers
might affect certain parameters and would or would not be effective at bringing
R0 beneath one and eradicating the disease. This is explored in [12] for a simpler
model.
For example using the expression for R0 in (2) and writing R0 ≡ R0(λ, φ, τ) with
the other parameters held fixed we can eliminate disease in the population (for both
models) either by:
(i) using health education to decrease the per capita needle-sharing rate λ beneath
the critical value λ0 given by the unique root of R0(λ0, φ, τ) = 1. This gives λ0 =
136.44 per year if the σi are non-zero and 135.44 per year if the σi are zero.
(ii) using health education to increase the effective syringe cleaning efficacy above
the unique root φ0 of the equation R0(λ, φ0, τ) = 1. This gives φ0 = 0.820 if the σi
are non-zero and 0.812 if the σi are zero.
or (iii) increasing the needle exchange rate τ above τ0 given by the unique root of
R0(λ, φ, τ0) = 1. This gives τ0 = 283.13 per year if the σi are non-zero and 234.21
per year if the σi are zero.
Of course in practice we would probably aim to use a combination of these
strategies to reduce R0 beneath one. We see that with the parameter values chosen
it looks as though introducing loss of HIV infectivity over time makes a small
difference to the amount of control effort need to eliminate the disease for decreasing
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needle sharing and increasing needle cleaning, but a larger significant difference for
needle exchange.
8. Summary. In this paper we have looked at an improved model for the spread of
HIV/AIDS amongst sharing IDUs. The infected needles and infected addicts were
each split into three groups representing the three levels of differential infectivity
amongst addicts. The key difference between this and previous work was that
infected needles did not remain infected indefinitely. Instead they lost infectivity at
rate depending on their infectious class.
We derived a differential equation model for the spread of the disease. We found
that there was a key threshold parameter R0, the basic reproduction number. For
R0 ≤ 1 there was a unique DFE which was GAS. For R0 > 1 the DFE was unstable.
There was a unique endemic equilibrium. For an approximation to this model this
unique endemic equilibrium was LAS when it existed. We discussed introducing
recruitment of new addicts and deaths from AIDS into the model and obtained
similar although less complete results (we did not show analytic stability of the
endemic equilibrium in this case). Simulations with realistic parameter values con-
firmed global asymptotic stability of the DFE for R0 ≤ 1 and suggested that for
R0 > 1 the system would always tend to the unique endemic equilibrium provided
that disease was initially present. Hence the qualitative behavior of the model with
or without differential loss of HIV infectivity over time included is the same. Finally
we used our theoretical results to determine the minimum control policies to just
eliminate HIV in the population by reducing needle sharing, or increasing needle
cleaning or exchange. The inclusion of loss of HIV infectivity over time makes a
small but possibly significant difference to quantities such as R0, the equilibrium
fraction of addicts infected and the critical education and needle cleaning control
strategies. There was a much larger difference in the equilibrium number of infected
needles and critical needle exchange rate.
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